MGC Pharma in Collaboration With Hempstreet Launches Artemic, a Mouth Spray for Severe COVID-19 Symptoms

'ArtemiC' is a nutraceutical mouth spray that helps in recovering from severe COVID-19 symptoms

HempStreet, India's first research to retail medicinal cannabis venture, has launched 'ArtemiC,' a nutraceutical mouth spray to speed up recovery for patients with severe COVID - 19 symptoms. ArtemiC has been launched in collaboration with MGC Pharma, a company with which HempStreet announced a partnership earlier this year. Headquartered in the UK, MGC Pharma is a pharmaceuticals company working on polyherbal formulations based on cannabis and other phytopharmaceuticals.

Founded in 2019, HempStreet has been working towards amalgamating the ancient science of Ayurveda with modern cannabis research to develop sustainable and economical solutions for mass ailments. HempStreet, through its collaboration with MGC Pharma, aims to create and bring to market phytopharma products to tackle mass ailments. With ArtemiC, the companies expect to reduce the symptoms of long COVID-19, which still affects more than 15 million people in India.

ArtemiC, includes four natural-based ingredients consisting of Curcumin, Boswellia serrata, Artemisinin and Vitamin C. ArtemiC Rescue and ArtemiC Support are the two variations of this product that will be available via medical practitioners and leading pharmacies. ArtemiC Rescue is an adjunctive treatment for the symptoms of COVID-19, whereas ArtemiC Support is a daily supplement that does not contain artemisinin. According to the double-blind, placebo-controlled clinical research findings, ArtemiC may minimize the severity of symptoms of COVID-19. In addition, the clinical trial demonstrated a significant reduction in one of the primary inflammatory markers related to COVID-19, C-reactive protein (CRP), an acute inflammatory protein that increases up to 1,000-fold at sites of infection or inflammation.

Commenting on the launch, Abhishek Mohan, Founder & CEO of HempStreet, said, "HempStreet and MGC Pharma are committed to bringing thoroughly studied, incredibly effective, and ethically dispensed phytomedicines to treat widespread illnesses that affect people worldwide. An observational open-label controlled clinical trial of ArtemiC, showed that the formulation demonstrated its efficacy in treating patients with severe COVID-19 for the first time. An estimated 15 million people in India are said to be suffering from “long covid” symptoms, making it a hidden mass ailment on its own. We look forward to helping patients nationwide with our products."

Further, Roby Zomer, Managing Director and CEO of MGC Pharma, said, "Entry into significant global markets such as India is paramount to MGC Pharma's strategy of advancing phytomedicine adoption globally. The latest observational trial results have expanded the possibilities for using ArtemiC in patients with severe COVID-19. In addition, working with HempStreet has facilitated access to our proprietary plant inspired medicines for millions of people in India who are still affected by the symptoms of COVID-19. MGC Pharma has always placed the treatment of patients at the heart of everything we do, and these results are promising signs for those who the disease has most severely impacted."

With a vast range of cannabis-based medication in Ayurveda and partnerships with ayurvedic doctors, HempStreet is poised to reshape how mass ailments are addressed. Furthermore, the company recently partnered with the Amrita School of Ayurveda to receive clinically supported solutions to aid in their fight against mass ailments. Additionally, the company also expanded its product portfolio and launched Sarpagandha Vati recently to help treat Hypertension and Insomnia through ayurvedic formulations.

About HempStreet

HempStreet is India's first research to retail medicinal cannabis venture, working towards amalgamating the age-old science of Ayurveda with modern cannabis research to develop sustainable and economical solutions for mass ailments. All of this while ensuring end-to-end blockchain technology-based supply chain tracking to minimize any chance of abuse. HempStreet's dispensation network of more than 11000 partner clinics across 26 states of India is a testament to the efficacy of the formulations and the trust of medical practitioners in the brand. In addition, the company is India's first medicinal cannabis venture to have been awarded the prestigious Biotechnology Ignition Grant (BIG) of BIRAC. Recently HempStreet partnered with Gynica, an R&D company based out of Israel focused on changing the culture of gynecological treatment through clinically proven, cannabinoid-based solutions.

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based Pharmaceutical company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments for unmet medical conditions.The Company’s founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australia. MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development. MGC Pharma has partnered with renowned institutions and academia to optimize the development of targeted plant inspired medicines, to be produced in the Company’s EU-GMP Certified manufacturing facilities. MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

HempStreet Expands Product Portfolio, Launches Sarpagandha Vati, to Combat Hypertension

HempStreet, India's first research to retail venture in the ayurvedic cannabis sector, has launched Sarpagandha Vati. Coming in the form of a tablet, Sarpagandha Vati helps treat Hypertension and Insomnia due to its calmative properties.

HempStreet’s dispensation works through a network of doctors who can buy the product via HempStreet’s B2B channels. This medicine is safe and reliable for middle and even old age people (39-70 years) who are at higher risk of side effects. The classical ayurvedic formulation outperforms other drugs in the same therapeutic range when combined with more potent herbs such as Vijaya (Cannabis Sativa) and Jatamansi (Nardostachys Jatamansi).

Each tablet of ‘Sarpagandha Vati’ contains Sarpagandha (262.20 mg), Khurasani Ajwain (52.44 mg), Jatamansi (26.22 mg), Vijaya (26.22 mg) and Pipalimula (4.92 mg). This Ayurvedic medicine calms the nervous system, aids in the maintenance of normal blood pressure, and maintains oxygen balance that helps regulate blood pressure in hypertensive patients. Additionally, Sarpagandha Vati’s diuretic and detoxifying properties benefit people with the following health and lifestyle issues:

• Help manage Epilepsy and Delirium
• Help combat anxiety disorder
• Help curb the desire for Alcohol
• Induce natural sleep to defy Insomnia

While conventional medications have serious health consequences, Ayurveda offers a natural, holistic, safe, and effective alternative to alleviate the condition of Hypertension. Sarpagandha Vati aims at providing a reliable and safe ayurvedic solution to hypertensive patients by regulating their blood pressure.

About HempStreet

HempStreet is India's first research to retail medicinal cannabis venture, working towards amalgamating the age-old science of Ayurveda with modern cannabis research to develop sustainable and economical solutions for mass ailments. All of this while ensuring end-to-end blockchain technology-based supply chain tracking to minimize any chance of abuse. HempStreet's dispensation network of more than 11000 partner clinics across 26 states of India is a testament to the efficacy of the formulations and the trust of medical practitioners in the brand. 

The company is also India's first medicinal cannabis venture to have been awarded the prestigious Biotechnology Ignition Grant (BIG) of BIRAC. Recently HempStreet partnered with Gynica, an R&D company based out of Israel focused on changing the culture of gynecological treatment through clinically proven, cannabinoid-based solutions.

Medical Cannabis Startup Hempstreet and Amrita School of Ayurveda Tie-Up to Fight Against Mass Ailments

Through this partnership, HempStreet aims to build solutions to help them in their fight against mass ailments.

HempStreet, India's first research to retail venture in the ayurvedic cannabis sector, has partnered with Amrita School of Ayurveda. Amrita School of Ayurveda, based in Kerala, was founded in 2004 and is a well-known Ayurvedic education facility both nationally and internationally. Through this collaboration, HempStreet aims to receive clinically supported solutions to aid in their fight against mass ailments.

HempStreet started with the vision to harness the power of ayurveda and utilize responsibly dispensed cannabis based medication to tackle chronic ailments. HempStreet’s partnership with Amrita School of Ayurveda is one step further to meet the nation's needs of managing ailments through modern Ayurveda. Amrita School of Ayurveda, part of Amrita University, is ranked fifth in the National Institutional Ranking Framework (NIRF) Rankings 2021. Amrita School takes a unique approach to blending ancient philosophies and health science by cultivating a new breed of Ayurvedic physicians to fulfill the mission of creating a patient-centered and integrated health care delivery system.

Commenting on the partnership, Abhishek Mohan, Founder & CEO, HempStreet, said, “We are very excited to announce this partnership with Amrita School of Ayurveda and its affiliate R&D organizations to work towards clinical validation of formulations to address several mass ailments. This aligns with our policy of partnering with the best in class. With this partnership, we strive to further our mission to harness the power of Ayurveda via cannabis-based medication with a layer of clinical validation. This fits our global strategy of best-in-class partnerships across Europe, the US and Israel.”

Adding to this, Dr P. Ram Manohar, Head, Centre for Advanced Research In Ayurveda (ACARA), said, "We are thrilled to be collaborating with HempStreet. Our goal is to promote the expansion and advancement of Ayurvedic education, and working with HempStreet will help us close the knowledge gap between cutting-edge technological advancements and traditional medicine based on ancient wisdom. By bringing tradition and scientific research together, we can pave the way for contemporizing Ayurveda to meet global health care needs.”

HempStreet is poised to reshape the way mass ailments are addressed by raising awareness about the use of cannabis for pain management to address one of the health sector's most pressing issues. The company recently collaborated with over 400 Ayurvedic doctors in Mumbai to bolster this. Furthermore, to strengthen the R&D and distribution segment, HempStreet also partnered with MGC Pharma and Gynica earlier this year.

About HempStreet

HempStreet is India's first research to retail medicinal cannabis venture, working towards amalgamating the age-old science of Ayurveda with modern cannabis research to develop sustainable and economical solutions for mass ailments. All of this while ensuring end-to-end blockchain technology-based supply chain tracking to minimize any chance of abuse. HempStreet's dispensation network of more than 11000 partner clinics across 26 states of India is a testament to the efficacy of the formulations and the trust of medical practitioners in the brand. The company is also India's first medicinal cannabis venture to have been awarded the prestigious Biotechnology Ignition Grant (BIG) of BIRAC. Recently HempStreet partnered with Gynica, an R&D company based out of Israel focused on changing the culture of gynecological treatment through clinically proven, cannabinoid-based solutions.

About Amrita School of Ayurveda:

Amrita School of Ayurveda, Amritapuri was established in 2004 and managed by Mata Amritanandamayi Math Trust. The college has developed into a prestigious centre for education in Ayurveda, nationally as well as internationally, under the gracious guidance of its founder and spiritual guru, Mata Amritanandamayi Devi. The mission of the school is to provide a value-based education and mold the character of our younger generation through synergy of science and spirituality so that their earnest endeavor to achieve progress and prosperity in life is matched by an ardent desire to extend selfless service to the society, one complementing the other.

Hempstreet Becomes India's 1st Medical Cannabis Company To Receive Govt Biotech Ignition Grant of Rs.50 Lakh

HempStreet, a research to retail company in the ayurvedic cannabis sector, has received a grant of about Rs 50 lakh from the Government of India for research on cannabis. With this, the company will do research and development work about the use of cannabis in Ayurvedic medicines.

It is the first medical cannabis company that has received the Biotechnology Ignition Grant (BIG) from the Biotechnology Industry Research Assistance Council (BIRAC) of the Government of India for research on cannabis.

With this, the company will do research and development work about the use of cannabis in Ayurvedic medicines. With this, the company will do research and development work about the use of cannabis in Ayurvedic medicines.

Prior to this, Bharat Biotech have received grants from BIG, which were engaged in research and development work of Covid vaccine.

Abhishek Mohan, Co-Founder and CEO, HempStreet said, “This award and the grant validates our efforts to build a world-class organization and take the Indian medical cannabis industry to its rightful place. We want to be a Make in India brand for the world."

Hempstreet claims that it is conducting research with leading scientists of the country about the use of cannabis in the treatment of diseases that affect about 300 million Indians. HempStreet claims to have a network of over 220 Ayurvedic clinics serving around 60,000 doctors across the country and have served about 35 million patients.